Skip to main content
Fig. 6 | BMC Neuroscience

Fig. 6

From: Neuroprotective effects of HTR1A antagonist WAY-100635 on scopolamine-induced delirium in rats and underlying molecular mechanisms

Fig. 6

Effects of WAY-100635 treatment on cytokine release into CSF, NLRP3 expression and signaling pathways activation in hippocampus and BLA. a ELISA analysis of cytokine release into CSF of control, scopolamine-treated and WAY-100635 treatment groups. b Western blotting analysis of NLRP3 expression and phosphorylated PI3K [phosphor-PI3K (p85α)], AKT [phosphor-AKT (Ser473)] and S6K [phosphor-S6K] and GAPDH in hippocampus and BLA from different groups rats. ci Quantitative values of western blot analysis. a: Saline, b: Saline + WAY-100635, c: scopolamine, d scopolamine + WAY-100635, e: normal + WAY-100635. ***p < 0.001 by comparison against other groups

Back to article page